Clinic
Prime Healthcare Services - Reno LLC
Prime Healthcare Services - Reno LLC was paid $15.09M by Medicaid between Jan 2018 and Dec 2024, across 233 billing codes. Its largest line is 99284, emergency room visit (serious) — 19% of everything it billed.
33Billing provider infoPRIME HEALTHCARE SERVICES - RENO LLC
RENO, NV 89503
RENO, NV 89503
33aNPI1801152566assigned 04/06/2012
33bProvider typeClinic/Center
28Total paid$15.09M
24GClaims825,352
24DCodes billed233
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinic/Center providers in Nevada
Rank by total paid#4 of 62
Median peer was paid$254K
This provider vs. median59×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official DOAN, CHRISTOPHER controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 74,920 | $1.47M | |
| 2019 | 145,411 | $2.61M | |
| 2020 | 133,724 | $2.35M | |
| 2021 | 142,757 | $2.37M | |
| 2022 | 134,091 | $2.35M | |
| 2023 | 112,990 | $2.18M | |
| 2024incomplete | 81,459 | $1.75M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 19% | 37,729 | 31,168 | $2.89M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 18% | 25,574 | 20,841 | $2.71M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 15% | 48,954 | 38,973 | $2.23M |
| G0378 | Hospital observation service, per hour | 4.3% | 7,156 | 3,278 | $646K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.0% | 3,516 | 3,035 | $605K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.7% | 6,011 | 5,086 | $410K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.5% | 3,086 | 2,761 | $371K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.7% | 15,236 | 12,085 | $263K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.5% | 6,413 | 4,856 | $223K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.4% | 6,507 | 1,958 | $209K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.3% | 4,681 | 3,956 | $193K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.2% | 9,867 | 6,587 | $189K |
221 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.2% | 9,122 | $175K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.1% | 2,667 | $168K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.1% | 761 | $165K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 57,583 | $150K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 799 | $150K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 4,597 | $139K |
| 80053 | Comprehensive metabolic panel | <1% | 39,175 | $139K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 17,103 | $133K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 12,335 | $129K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 30,589 | $126K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 2,090 | $121K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,659 | $120K |
| 0450 | Emergency room services | <1% | 2,427 | $107K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 5,924 | $106K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 9,000 | $98K |
| 71045 | Radiologic examination, chest; single view | <1% | 17,754 | $94K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 7,875 | $93K |
| 76830 | Ultrasound, transvaginal | <1% | 1,320 | $84K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,708 | $77K |
| 93971 | <1% | 1,587 | $63K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,137 | $61K |
| 10060 | <1% | 973 | $58K | |
| 76801 | <1% | 971 | $55K | |
| 59025 | Fetal non-stress test | <1% | 1,839 | $55K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 18,821 | $54K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,764 | $53K |
| 36415 | Collection of venous blood by venipuncture | <1% | 58,675 | $51K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,740 | $41K |
| 83690 | <1% | 14,965 | $37K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 6,801 | $37K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,431 | $36K |
| 70486 | <1% | 372 | $36K | |
| 84484 | <1% | 12,581 | $34K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 801 | $32K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 184 | $32K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 10,822 | $32K |
| 72110 | <1% | 1,779 | $32K | |
| 90715 | <1% | 1,611 | $32K | |
| 83880 | <1% | 3,726 | $31K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,984 | $31K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,984 | $31K |
| 73130 | <1% | 1,877 | $28K | |
| 84703 | <1% | 9,049 | $28K | |
| 73630 | <1% | 1,989 | $27K | |
| 73610 | <1% | 1,618 | $26K | |
| 97597 | <1% | 2,456 | $25K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,584 | $24K |
| 73564 | <1% | 1,532 | $24K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 14,795 | $24K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 4,469 | $23K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,122 | $22K |
| 87400 | <1% | 3,820 | $22K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 4,220 | $21K |
| J3490 | Unclassified drugs | <1% | 10,950 | $20K |
| 73110 | <1% | 1,139 | $20K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,733 | $19K |
| 96376 | <1% | 3,419 | $19K | |
| 73030 | <1% | 1,543 | $18K | |
| 81001 | <1% | 15,524 | $17K | |
| 29125 | <1% | 732 | $16K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,626 | $15K |
| 71250 | <1% | 202 | $15K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 299 | $15K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,211 | $14K |
| 87040 | <1% | 4,165 | $14K | |
| 84702 | <1% | 2,145 | $13K | |
| 82040 | <1% | 8,257 | $13K | |
| 93970 | <1% | 177 | $12K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 14,162 | $12K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 5,582 | $11K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 320 | $11K |
| 74021 | <1% | 804 | $10K | |
| 83605 | <1% | 3,113 | $10K | |
| 93017 | <1% | 961 | $10K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 502 | $10K |
| 87186 | <1% | 3,098 | $8K | |
| 76770 | <1% | 139 | $8K | |
| 87081 | <1% | 2,817 | $8K | |
| 87077 | <1% | 3,160 | $8K | |
| 73502 | <1% | 542 | $7K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 76 | $7K |
| 81025 | <1% | 3,407 | $7K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 155 | $7K |
| 81003 | <1% | 7,962 | $6K | |
| 85379 | <1% | 1,547 | $6K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 4,149 | $6K |
| 74018 | <1% | 549 | $5K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 100 | $5K |
| 84145 | <1% | 620 | $5K | |
| 97162 | <1% | 113 | $4K | |
| 86756 | <1% | 576 | $4K | |
| 99199 | Unlisted special service, procedure or report | <1% | 81 | $4K |
| 74019 | <1% | 316 | $4K | |
| 73562 | <1% | 276 | $4K | |
| 83735 | <1% | 2,373 | $4K | |
| 99406 | <1% | 2,918 | $4K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 6,241 | $4K |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 214 | $4K |
| Z7502 | <1% | 90 | $3K | |
| 72072 | <1% | 243 | $3K | |
| 87420 | <1% | 512 | $3K | |
| 74022 | <1% | 211 | $3K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 13,547 | $3K |
| 85027 | <1% | 1,430 | $3K | |
| 85610 | <1% | 3,488 | $3K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,523 | $3K |
| 85730 | <1% | 1,964 | $3K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 6,186 | $2K |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 63 | $2K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 4,128 | $2K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,591 | $2K |
| 82962 | <1% | 5,519 | $2K | |
| 87808 | <1% | 439 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,597 | $2K |
| 86703 | <1% | 357 | $2K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 564 | $2K |
| 73080 | <1% | 144 | $2K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 13 | $2K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 34 | $2K |
| 80299 | <1% | 677 | $2K | |
| 87807 | <1% | 287 | $2K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,796 | $2K |
| 72050 | <1% | 88 | $2K | |
| 71101 | <1% | 121 | $2K | |
| 10061 | <1% | 12 | $2K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 701 | $2K |
| J2704 | Injection, propofol, 10 mg | <1% | 5,637 | $2K |
| 97163 | <1% | 38 | $2K | |
| 86141 | <1% | 445 | $2K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 953 | $1K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 44 | $1K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 838 | $1K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,539 | $1K |
| 86900 | <1% | 1,745 | $1K | |
| 85007 | <1% | 1,156 | $1K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 30 | $1K |
| 85651 | <1% | 1,329 | $1K | |
| 86901 | <1% | 1,234 | $1K | |
| 12001 | <1% | 45 | $1K | |
| 80061 | Lipid panel | <1% | 754 | $1K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 111 | $1K |
| 87210 | <1% | 720 | $1K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 57 | $1K |
| 99156 | <1% | 154 | $1K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 1,542 | $1K |
| 99152 | <1% | 79 | $1K | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 694 | $1K |
| 84439 | <1% | 407 | $971.29 | |
| 86140 | <1% | 662 | $946.07 | |
| 86850 | <1% | 1,022 | $921.21 | |
| J3486 | Injection, ziprasidone mesylate, 10 mg | <1% | 142 | $904.66 |
| 99157 | <1% | 93 | $900.53 | |
| 87147 | <1% | 350 | $856.28 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 2,620 | $772.39 |
| 86592 | <1% | 327 | $709.70 | |
| T1999 | Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" | <1% | 43 | $704.28 |
| 29515 | <1% | 38 | $665.56 | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 20 | $662.54 |
| 73590 | <1% | 70 | $643.49 | |
| C1769 | Guide wire | <1% | 336 | $637.15 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 530 | $625.92 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 108 | $548.50 |
| 82947 | <1% | 590 | $540.92 | |
| 99201 | <1% | 46 | $463.60 | |
| 93356 | <1% | 116 | $460.24 | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 524 | $411.93 |
| 76642 | <1% | 12 | $402.78 | |
| 29505 | <1% | 17 | $380.96 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,177 | $374.62 |
| 87581 | <1% | 22 | $335.16 | |
| 87486 | <1% | 22 | $335.16 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 22 | $335.16 |
| J1815 | Injection, insulin, per 5 units | <1% | 161 | $311.57 |
| 82010 | <1% | 102 | $283.62 | |
| 96367 | <1% | 52 | $240.26 | |
| 84550 | <1% | 189 | $239.70 | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 430 | $235.15 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 707 | $234.11 |
| 70360 | <1% | 14 | $223.20 | |
| 80076 | <1% | 73 | $217.78 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 66 | $186.81 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 75 | $185.14 |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 52 | $175.96 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 936 | $162.36 |
| 82550 | <1% | 81 | $151.05 | |
| 82728 | <1% | 31 | $147.70 | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 172 | $144.31 |
| 99070 | <1% | 13 | $139.21 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 49 | $130.42 |
| 87070 | <1% | 87 | $117.60 | |
| 87205 | <1% | 123 | $113.61 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 922 | $104.30 |
| 84100 | <1% | 75 | $90.47 | |
| 87806 | <1% | 25 | $65.52 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 17 | $65.44 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 64 | $48.70 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 34 | $48.36 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 19 | $38.16 |
| 83615 | <1% | 16 | $32.48 | |
| 82009 | <1% | 13 | $30.80 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 899 | $28.23 |
| 82565 | <1% | 31 | $28.00 | |
| 80143 | <1% | 24 | $27.96 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 103 | $21.92 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 495 | $21.85 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 26 | $19.51 |
| 80179 | <1% | 12 | $18.64 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 20 | $16.56 |
| 80329 | <1% | 811 | $13.67 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 298 | $11.65 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 181 | $5.76 |
| Q0177 | Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 179 | $2.55 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 267 | $1.52 |
| 0011A | 0% | 15 | $0.00 | |
| A4930 | Gloves, sterile, per pair | 0% | 41 | $0.00 |
| 0012A | 0% | 12 | $0.00 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 57 | $0.00 |
| A4618 | Breathing circuits | 0% | 19 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 122 | $0.00 |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | 0% | 42 | $0.00 |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 0% | 23 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDOAN, CHRISTOPHER (MANAGING ASSOCIATE GENERAL COUNSEL)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.